Menu
Enrolling by invitation NCT05653310

Tradipitant for Functional Dyspepsia

Phase II Interventional Functional Dyspepsia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Tradipitant, Placebo.
Who it may be relevant to
Registry conditions: Functional Dyspepsia. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Tradipitant for Functional Dyspepsia

Overview

To evaluate the effects of tradipitant relative to placebo on gastric motor functions, satiation, and postprandial symptoms in patients with functional dyspepsia.

Interventions

  • Drug Tradipitant
    Tradipitant Capsule
  • Drug Placebo
    Placebo Capsule

Primary outcome measures

  • Accommodation gastric volumes measured by single photon emission computed tomography (SPECT) [Time frame: 4 Weeks]

Eligibility criteria

Inclusion criteria

  • Able to provide written consent
  • Body Mass Index (BMI) of 18-35 kg/m2
  • Absence of other diseases which could interfere with interpretation of study results

Exclusion criteria

  • Current H. pylori infection
  • Pregnancy or nursing
  • Recent history of Alcohol Use Disorder or Substance Use Disorder

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Basic science

Study locations

United States · 1 center
  • Mayo Clinic in Minnesota — Rochester

Identifiers

NCT: NCT05653310 · 21-012527

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗